Samsung Biologics ,Ltd. EBIT

The latest EBIT for 207940.KS is $2.3T as of September 2026. That compares with $2.1T in the prior-year period — up 10.3% year over year. That is above the Healthcare sector average of $99B. Investors often review this figure alongside Samsung Biologics ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 207940.KS's EBIT moved from $2.1T to $2.3T — a 10.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Samsung Biologics ,Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 207940.KS currently prints $2.3T for EBIT, while the sector average sits near $99B. That is roughly 2235.4% above the sector mean. Large gaps often invite a closer look at Samsung Biologics ,Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $2.3T for 207940.KS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting 207940.KS's EBIT ($2.3T), review year-over-year change from $2.1T, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.